123 related articles for article (PubMed ID: 31677255)
1. Enhanced functional recombinant factor IX production by human embryonic kidney cells engineered to overexpress VKORC1.
Pakdaman SF; Vatandoost J; Bos MHA
Biotechnol Prog; 2020 Mar; 36(2):e2938. PubMed ID: 31677255
[TBL] [Abstract][Full Text] [Related]
2. Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle.
Wajih N; Hutson SM; Owen J; Wallin R
J Biol Chem; 2005 Sep; 280(36):31603-7. PubMed ID: 16030016
[TBL] [Abstract][Full Text] [Related]
3. r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.
Hallgren KW; Qian W; Yakubenko AV; Runge KW; Berkner KL
Biochemistry; 2006 May; 45(17):5587-98. PubMed ID: 16634640
[TBL] [Abstract][Full Text] [Related]
4. Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ-carboxylation of a human vitamin K-dependent protein by the insect enzyme.
Vatandoost J; Zomorodipour A; Sadeghizadeh M; Aliyari R; Bos MH; Ataei F
Biotechnol Prog; 2012; 28(1):45-51. PubMed ID: 22012919
[TBL] [Abstract][Full Text] [Related]
5. Effect of propeptide amino acid substitution in γ-carboxylation, activity and expression of recombinant human coagulation factor IX.
Vatandoost J; Zarei Sani O
Biotechnol Prog; 2018 Mar; 34(2):515-520. PubMed ID: 29086495
[TBL] [Abstract][Full Text] [Related]
6. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system.
Wajih N; Sane DC; Hutson SM; Wallin R
J Biol Chem; 2005 Mar; 280(11):10540-7. PubMed ID: 15640149
[TBL] [Abstract][Full Text] [Related]
7. Improved activity and expression of recombinant human factor IX by propeptide engineering.
Vatandoost J; Bos MHA
Daru; 2019 Dec; 27(2):653-660. PubMed ID: 31637661
[TBL] [Abstract][Full Text] [Related]
8. Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins.
Hallgren KW; Hommema EL; McNally BA; Berkner KL
Biochemistry; 2002 Dec; 41(50):15045-55. PubMed ID: 12475254
[TBL] [Abstract][Full Text] [Related]
9. Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection.
Wajih N; Owen J; Wallin R
Thromb Res; 2008; 122(3):405-10. PubMed ID: 18177690
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.
Müller E; Keller A; Fregin A; Müller CR; Rost S
BMC Genet; 2014 Feb; 15():17. PubMed ID: 24491178
[TBL] [Abstract][Full Text] [Related]
11. VKOR paralog VKORC1L1 supports vitamin K-dependent protein carboxylation in vivo.
Lacombe J; Rishavy MA; Berkner KL; Ferron M
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321368
[TBL] [Abstract][Full Text] [Related]
12. Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain.
Caspers M; Czogalla KJ; Liphardt K; Müller J; Westhofen P; Watzka M; Oldenburg J
Thromb Res; 2015 May; 135(5):977-83. PubMed ID: 25747820
[TBL] [Abstract][Full Text] [Related]
13. Human cell lines: A promising alternative for recombinant FIX production.
de Sousa Bomfim A; Cristina Corrêa de Freitas M; Picanço-Castro V; de Abreu Soares Neto M; Swiech K; Tadeu Covas D; Maria de Sousa Russo E
Protein Expr Purif; 2016 May; 121():149-56. PubMed ID: 26802680
[TBL] [Abstract][Full Text] [Related]
14. A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
Fregin A; Czogalla KJ; Gansler J; Rost S; Taverna M; Watzka M; Bevans CG; Müller CR; Oldenburg J
J Thromb Haemost; 2013 May; 11(5):872-80. PubMed ID: 23452238
[TBL] [Abstract][Full Text] [Related]
15. GGCX mutants that impair hemostasis reveal the importance of processivity and full carboxylation to VKD protein function.
Rishavy MA; Hallgren KW; Wilson LA; Hiznay JM; Runge KW; Berkner KL
Blood; 2022 Oct; 140(15):1710-1722. PubMed ID: 35767717
[TBL] [Abstract][Full Text] [Related]
16. The carboxylation efficiency of the vitamin K-dependent clotting factors: studies with factor IX.
Blostein M; Cuerquis J; Landry S; Galipeau J
Haemophilia; 2008 Sep; 14(5):1063-8. PubMed ID: 18680528
[TBL] [Abstract][Full Text] [Related]
17. Improvement of the recombinant human coagulation factor IX expression by co-expression of a novel transcript of Drosophila γ carboxylase in a human cell line.
Moniri Javadhesari S; Zomorodipour A
Biotechnol Lett; 2020 Nov; 42(11):2147-2156. PubMed ID: 32514789
[TBL] [Abstract][Full Text] [Related]
18. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase.
Rishavy MA; Hallgren KW; Wilson L; Singh S; Runge KW; Berkner KL
Blood; 2018 Jun; 131(25):2826-2835. PubMed ID: 29592891
[TBL] [Abstract][Full Text] [Related]
19. Effect of prepropeptide replacement on γ-carboxylation and activity of recombinant coagulation factor IX.
Vatandoost J; Bos MHA
Biotechnol Lett; 2022 Aug; 44(8):975-984. PubMed ID: 35731352
[TBL] [Abstract][Full Text] [Related]
20. Tethered processivity of the vitamin K-dependent carboxylase: factor IX is efficiently modified in a mechanism which distinguishes Gla's from Glu's and which accounts for comprehensive carboxylation in vivo.
Stenina O; Pudota BN; McNally BA; Hommema EL; Berkner KL
Biochemistry; 2001 Aug; 40(34):10301-9. PubMed ID: 11513608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
